Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.

After hours: February 28 at 7:59:40 PM EST ...

UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in ...

Looking ahead to 2025, Moderna expects revenue of $1.5 to $2.5bn. Credit: Tada Images/Shutterstock. Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 – a sharp decline from the ...

Moderna posted a Q4 EPS loss of $(2.91), missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna’s norovirus vaccine trial is on FDA hold due to a ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...

Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data The findings, published Tuesday in Nature, are important for another key reason. The team’s work originally ...